Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Completed
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/23/2010
Locations: Houston, Houston, Texas
Conditions: Ocular Inflammation Associated With Blepharaconjunctivitis